Boehringer Ingelheim

"The acquisition is expected to be completed in March 2025. Torrent has been marketing these brands since 2022 as part of an existing co-marketing agreement with Boehringer Ingelheim India," the company said in a statement.

Lupin: Margin guidance downgrade keeps us cautious

The management of Lupin is confident of scaling back $200 million quarterly revenue run rate for US market by Q3, but at the same time, alluded to overall EBITDA margin guidance of 16-17 per cent in FY22

Boehringer Ingelheim earmarks EUR 1 million for COVID relief initiatives in India

The company is making available the relief fund to enable sustenance and livelihoods of underserved and tribal communities, and address medical needs of patients in India, through the 2021-22 fiscal, Boehringer Ingelheim said in a statement.

Sanofi, Boehringer Ingelheim close business swap in India

The closing of swap deal was for the exchange of Sanofi's animal health business and Boehringer Ingelheim's consumer healthcare (CHC) business in the country, a release said here.

Boehringer Ingelheim, Lupin sign pact for diabetes drug

According to the agreement, "Lupin will market and sell Empagliflozin under a separate brand name Gibtulio which will be promoted by Lupin's specialty field force," the companies said in a joint statement.

Lupin, Boehringer Ingelheim to co-mkt linagliptin in India

Boehringer Ingelheim will continue to sell its linagliptin under the brand names Trajenta (monotherapy) and TrajentaDuo (fixed-dose combination with metformin) through their existing sales force and network.

Lupin up 1%, forms joint strategic alliance with Boehringer

Lupin will market and sell linagliptin under a separate brand name Ondero (monotherapy) and Ondero Met (fixed-dose combination with metformin) which will be promoted by Lupin‘s 400 strong dedicated Diabetes specialty field force.

USFDA approves Gilotrif (afatinib)

Boehringer Ingelheim announced that the US Food and Drug Administration has approved afatinib tablets under the US brand name GILOTRIFTM for oral use.

New clot preventer as well as warfarin with less bleeding

The blood clot preventer Eliquis, sold by Pfizer Inc and Bristol-Myers Squibb Co, proved as effective as widely used warfarin in treating a dangerous condition known as venous thromboembolism and caused far less bleeding, according to data from a large clinical trial.

Boehringer Ingelheim, Eli Lilly launch Complications Combat

Boehringer Ingelheim and Eli Lilly & Company have launched an educational digital game for type 2 diabetes called Complications Combat.

FDA aapproves generic version of cancer drug Doxil

US health regulators have approved a generic version of the cancer drug Doxil in a move that could ease a months-long shortage that has threatened the lives of thousands of patients.

Dr Reddy's gets US nod for osteoporosis drug

Dr Reddy's Laboratories has received US Food and Drug Administration's approval for selling ibandronate sodium tablets used to treat osteoporosis, the regulator's website showed on Thursday.

Novo Nordisk bets on blockbuster drug to retain top spot

Multi-national drug companies are queuing up to enter India and tap its growing anti-diabetes drug market. But Novo Nordisk, which has been in the Indian insulin market for 75 years, is not worried, reports CNBC-TV18's Archana Shukla.